State-of-the-Art Clinical Symposium

CE/MOC information for the State-of-the-Art Clinical Symposium 2027 to be announced.

For CE/MOC information about the State-of-the-Art Clinical Symposium 2026, please see the 2026 meeting section below.

Instructions to Claim CE/MOC Credit

Credit claiming is available after the activity starts.

See instructions to claim credit on the CE & MOC page.

ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Education (CE) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CE activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CE activity.

Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:

1. Advisor or review panel member
2. Consultant
3. Employee
4. Officer or Board Member
5. Grant/research support
6. Speaker/honoraria includes speakers bureau, symposia, and expert witness
7. Independent contractor
8. Executive role and/or ownership interest
9. Royalties and/or patient beneficiary
10. Intellectual property/patents
11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
12. Private investigator
13. Expert witness
14. Equity interest
15. Other: specify details

None: Has no relevant financial relationship(s) with ineligible companies to disclose.

All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.

• SOTA 2027 Financial Relationships Disclosures to be announced
• View ACR's ACCME disclosure practices

See 2026 disclosures in the 2026 meeting section below.

The State-of-the-Art Clinical Symposium 2026 was an in-person only event that took place April 24–26 in Rosemont, IL.

During the State-of-the-Art Clinical Symposium (SOTA), key opinion leaders will deliver a range of content in areas such as therapeutic developments, recent research findings, and scientific advances, in an environment conducive to dialogue and networking.

Target Audience
Rheumatologists (physicians) in clinical care and/or research, fellows in training, division directors, program directors, assistant program directors, physician assistants, nurse practitioners, pharmacists, nurses, and epidemiologists.

Learning Objectives
Upon completion of this activity, participants should be able to:

• Review the most up-to-date evidence-based treatment approaches in the diagnosis and management of rheumatic diseases including psoriatic arthritis, rheumatoid arthritis, and osteoarthritis.
• Review more complex clinical presentations, disease pathology, and treatment modalities in patients with lupus, refractory or recurrent idiopathic inflammatory myopathy, sarcoidosis, scleroderma.
• Summarize updated guidelines for complex manifestations of rheumatic disease, specifically pulmonary hypertension and interstitial lung disease, and implement current recommendations for screening and treatment.
• Review most up-to-date guidelines and clinical recommendations in pediatric rheumatology diseases.
• Recognize Lyme disease and other tick-borne illnesses that present phenotypically similar to rheumatic disease and review best treatment modalities for these patients.

Program Schedule & Syllabi

State-of-the-Art Clinical Symposium 2026 Program Agenda

State-of-the-Art Clinical Symposium 2026 Online Program

Registered attendees can access the syllabi during the meeting and for 12 months after the meeting. To access syllabi, login and go to My Learning.

CE & MOC Information

CE

Accreditation Statement

In support of improving patient care, the American College of Rheumatology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CE credit must be claimed by June 25, 2026, at 11:59 PM ET.

Joint Accreditation (JA) Statement

This activity was planned by and for the healthcare team, and learners will receive 9.00 Interprofessional Continuing Education credits for learning and change.

CME Designation Statement

The ACR designates this live activity for a maximum of 9.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Designation Statement

This program has been reviewed and is acceptable for up to 9.00 nursing contact hours.

See the ACR’s CE Mission Statement. For more information, download the AMA PRA Booklet.

All participating healthcare professionals, including physicians and nurses, should claim only the credit commensurate with the extent of their participation in this activity.

MOC

MOC Recognition Statement: American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By completing this activity, you provide the ACR permission to share completion data with the ACCME and the certifying board.

After submitting a reflective statement with key takeaways from the meeting, MOC points will be applied for ABIM diplomates to the ABIM diplomate number and date of birth provided when you registered. Points are sent nightly to ACCME and then transferred to the ABIM Physician Portal. Please allow at least 48 hours for points to display in the portal.

MOC points must be claimed by June 25, 2026, at 11:59 PM ET.

Instructions to Claim CE/MOC Credit

Credit claiming is available after the activity starts.

See instructions to claim credit on the CE & MOC page.

Financial Relationships Disclosures

ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Education (CE) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CE activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CE activity.

Nature of Financial Relationships
All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to:

1. Advisor or review panel member
2. Consultant
3. Employee
4. Officer or Board Member
5. Grant/research support
6. Speaker/honoraria includes speakers bureau, symposia, and expert witness
7. Independent contractor
8. Executive role and/or ownership interest
9. Royalties and/or patient beneficiary
10. Intellectual property/patents
11. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
12. Private investigator
13. Expert witness
14. Equity interest
15. Other: specify details

None: Has no relevant financial relationship(s) with ineligible companies to disclose.

All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.

• View SOTA 2026 Financial Relationships Disclosures
• View ACR's ACCME disclosure practices

Acknowledgement of Commercial Support

We gratefully acknowledge that the State-of-the-Art Clinical Symposium 2026 is supported in part by unrestricted educational grants from the following commercial supporters. We extend our sincere thanks to these organizations for their generous contributions: UCB and Genentech.